Quick Search:

uzh logo
Browse by:

Zurich Open Repository and Archive

Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-35594

Recher, M; Sahrbacher, U; Bremer, J; Arndt, B; Steiner, U; Fontana, A (2012). Treatment of inclusion body myositis: is low-dose intravenous immunoglobulin the solution? Rheumatology International, 32(2):469-472.

[img] PDF - Registered users only
View at publisher


Inclusion body myositis (IBM), the most common inflammatory myopathy in the elderly, is often resistant to various forms of therapy. Placebo-controlled treatment trials with high dose intravenous immunoglobulins (IVIG) have shown disease amelioration in some but not all patients. Here, we present the informative case of a 70-year-old woman with diagnosed inclusion body myositis that showed progressive muscle weakness without treatment and following immuno-suppressive treatment with corticosteroids and azathioprine. A trial with low-dose intravenous immunoglobulins was started at that time. The patient responded rapidly to low dose IVIG treatment with amelioration of muscle strength and normalization of CK serum activities. Our results demonstrate that IBM patients may respond to low-dose IVIG treatment which has important clinical and economic consequences.


3 citations in Web of Science®
4 citations in Scopus®
Google Scholar™



1 download since deposited on 05 Nov 2010
0 downloads since 12 months

Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Immunology
04 Faculty of Medicine > Institute of Experimental Immunology
Dewey Decimal Classification:570 Life sciences; biology
610 Medicine & health
Deposited On:05 Nov 2010 10:07
Last Modified:05 Apr 2016 14:14
Publisher DOI:10.1007/s00296-009-1290-z
PubMed ID:20044785

Users (please log in): suggest update or correction for this item

Repository Staff Only: item control page